Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-26

FDA Approved: BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE — Original Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved Hikma Pharmaceuticals USA's generic fixed-dose combination of butalbital, acetaminophen, caffeine and codeine phosphate (Original Application).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Butalbital, Acetaminophen, Caffeine and Codeine Phosphate

Snippet

ORIG AP for BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE)